An analysis of ASPREE trial data links low-dose aspirin to lower dementia incidence in a specific genetic subgroup, though major bleeding risks remain high.
On September 29, 2026, researchers published an analysis of more than 13,500 ASPREE trial participants in the journal Alzheimer’s & Dementia. The Monash University study found that low-dose aspirin was associated with lower dementia incidence specifically among people with a high platelet-count genetic score.
The new analysis sought to understand if genetic differences change how individuals respond to preventative interventions. Researchers screened 5,182 polygenic scores to look for interactions between aspirin allocation and either dementia or major bleeding. This massive computational process relied on the available study record from the broader trial population. The scientific team utilized this data to isolate one specific genetic profile for closer examination.
The strongest reported association involved participants in the highest fifth of a specific platelet-count genetic score. Within this subgroup, dementia was reported in 1 percent of those allocated aspirin. For participants allocated a placebo, dementia occurred in 3.3 percent of cases. These figures correspond to about a 70 percent lower relative risk in that specific cohort. The concentration of this association within one genetic subgroup is the central focus of the new publication.
A separate study-record summary quantified this association carefully using hazard ratios. It reported a dementia hazard ratio of 0.28 in the highest quintile of the platelet-count score. The 95 percent confidence interval for this statistical finding was 0.15 to 0.52. These detailed metrics highlight a pronounced difference between the targeted subgroup and the broader trial population.
These findings provide a sharp departure from the overall ASPREE trial results. The report notes that earlier trials did not find dementia prevention when participants were considered together as a whole group. To understand the scale of cognitive health concerns, the report provides population estimates from Dementia Australia. The organization estimates that 446,500 Australians are living with dementia in 2026.
Dementia Australia projects this number to exceed one million by 2065. These figures offer context for the scale of the condition across the population. They do not serve as evidence about the effectiveness of aspirin itself. The stark population projections highlight why researchers are actively searching for targeted cognitive health protection pathways.
This study introduces a potential precision-prevention hypothesis into the medical conversation around cognitive longevity. The research suggests that inherited differences related to platelet count might explain a critical discrepancy. It shows how an average result across a whole clinical trial could differ from an association observed in a smaller subgroup. This shift in perspective alters how medical professionals evaluate previous broad population studies.
The source article provides additional context regarding the biological mechanisms at play. The result points toward platelet biology rather than established genetic risk factors for Alzheimer’s disease. Previous studies have documented links between platelet activation, platelet aggregation, and dementia. The exact role of overall platelet count has historically been less clear to researchers.
The Monash team presents this specific platelet-count finding as a direction for further investigation. It is not intended to be a settled explanation for how cognitive decline develops. Lead author Dr Peter Fransquet said the study suggests genetics could one day help identify appropriate candidates for treatment. This points to a future where brain aging and neuroplasticity interventions could rely on individual biological profiles rather than a universal approach.
Evaluating any medical intervention requires a careful review of potential adverse events. The reported dementia association must be weighed against a higher reported major-bleeding proportion. In the high-score subgroup, major bleeding was reported in 4.4 percent of participants allocated aspirin. This rate was only 2.1 percent for participants who were allocated a placebo.
The study-record summary provides precise statistical measurements for this adverse outcome. It reports a hazard ratio of 2.13 for major bleeding among the highest quintile cohort. The 95 percent confidence interval for this bleeding risk ranged from 1.36 to 3.34. These figures demonstrate that the biological mechanism potentially protecting the brain also increases severe bleeding events.
The striking relative reduction in dementia risk requires careful context to avoid medical misinterpretation. The reported subgroup proportions describe the specific study cohort and do not establish an individual’s likely clinical benefit. Dr Fransquet cautioned that people should not start aspirin to prevent dementia based on this study. He advised that no one should begin this specific protocol without first consulting a doctor.
The increased risk of serious bleeding makes independent experimentation highly dangerous for older adults. Readers must view these results as early observational data rather than actionable personal health advice. For those reviewing their lifestyle and brain resilience strategies, pharmaceutical interventions demand strict clinical supervision. You should always discuss new research findings with your primary care physician before altering your daily habits.
The scientific process requires multiple phases of verification before a new hypothesis becomes standard medical care. Dr Fransquet stated that the team needs to confirm the finding in other independent studies. Single observational analyses, even those utilizing massive datasets, cannot serve as the sole basis for clinical guidelines. Researchers must replicate these genetic interactions in different populations to verify the results are reliable.
Following independent confirmation, the hypothesis must undergo rigorous prospective testing. The lead author called for a new trial designed specifically for people with the relevant genetic profile. This means researchers must recruit new participants based entirely on their platelet-count polygenic scores. They will then need to monitor these specific individuals over several years to track cognitive outcomes.
You should treat genetic testing as an ongoing research question right now. It is not a proven decision tool for immediate preventative care planning. A purpose-designed trial requires significant funding, ethical approvals, and extended observation periods. Because of these necessary scientific safeguards, targeted aspirin therapy for dementia remains years away from mainstream availability.
The Monash University analysis represents a critical evolution in the search for cognitive preservation strategies. By isolating a specific platelet-count genetic score, researchers found associations hidden within a larger trial population. This precision-prevention hypothesis suggests that blanket recommendations often fail to capture complex biological realities. Understanding these inherited differences might eventually explain why certain interventions only work for select groups of people.
The long-term trajectory of cognitive health research is clearly moving toward targeted biological pathways. As scientists continue to screen thousands of polygenic scores, medical protocols will likely become highly personalized. While these early genetic subgroup analyses are promising, they require patience and ongoing scientific scrutiny. You can learn more about established preventative habits by reviewing our memory and cognitive performance resources.
Discussing new genetic prevention research often becomes the responsibility of independent older adults and their primary care physicians. Confusion about what normal brain aging looks like can make evaluating these observational studies difficult, but FitBrainLab translates complex evidence on cognitive longevity into clear, practical guidance. Our research-led editorial approach helps you separate established medical facts from early findings without relying on hype. Explore Resources
Follow FitBrainLab for research-led insights on memory, focus, brain aging, nutrition and mental fitness after 60. Stay connected for new articles, practical guidance and ideas for a sharper, more engaged life.
Build habits that support memory, focus and a curious, connected life.
Read the Blog
